Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease
4
Citation
42
Reference
10
Related Paper
Citation Trend
Abstract:
Phosphorus reduction can prevent against vascular calcification (VC) in chronic kidney disease (CKD), but the mechanisms underlying its actions remain unclear. The aim of the present study was to determine the effect of a fortified phosphorus‑lowing treatment on VC in CKD. Serum levels of creatinine, blood urea nitrogen (BUN), fibroblast growth factor 23 (FGF23), calcium and phosphorus, and the plasma levels of parathyroid hormone (PTH) were determined in an animal model of CKD treated with or without lanthanum. Haematoxylin and eosin (H&E) staining was performed to examine the structure of kidney tissues. Western blot analysis was performed to compare the levels of total‑ (t‑) extracellular signal‑related kinase (ERK) and phospho‑ (p‑)ERK among the different experimental groups to investigate the effect of FGF23 on p‑ERK expression. In the animal model, administration of adenine increased the serum levels of creatinine, BUN, FGF23 and phosphorus but decreased the serum levels of calcium. In addition, adenine treatment increased the plasma levels of PTH. H&E staining showed that lanthanum treatment did not alter the severity of renal cortex injury. Furthermore, the levels of t‑ERK levels did not notably differ between the Adenine‑free, Adenine‑vehicle and Adenine‑lanthanum groups, whereas the levels of p‑ERK and aortic calcium in the Adenine‑vehicle group were significantly upregulated. In addition, ectopic overexpression of FGF23 increased the levels of p‑ERK, Msx2 and Osx in a dose‑dependent manner. Furthermore, a total of 48 patients were enrolled in the present study. In the fortified group, the serum levels of FGF23, phosphorus and PTH were significantly reduced, whereas the serum levels of calcium were significantly increased, indicating an enhanced preventative effect in the fortified group. The results of the present study suggest that FGF23 may be used as a therapeutic target in the management and prevention of VC in CKD.Keywords:
Blood urea nitrogen
Rhabdomyolysis, a potentially life-threatening syndrome, is not an uncommon condition with around 38,000 cases been reported in the USA in 2000. The risk of developing acute renal failure in the initial days of presentation can be as high as 40% and approximately 28-37% of patients require short-term hemodialysis. This report discusses a case of rhabdomyolysis after seizures in which blood urea nitrogen (BUN), creatinine, and BUN/creatinine levels were examined during the course of illness in the hospital. We found that the BUN/creatinine ratio is not a reliable indicator of renal function in rhabdomyolysis. Potassium levels can be a better marker for the early recognition of acute renal failure and an indication for prompt treatment with dialysis, which is crucial to prevent fatal complications.
Blood urea nitrogen
Cite
Citations (13)
The effect of blood flow rates (BFRs) in continuous venovenous hemodiafiltration (CVVHDF) on the clearances of blood urea nitrogen (BUN) and creatinine was studied using a retrospective chart review. Fifteen patients, 9 males and 6 females aged 50-85 years, were included in the study. Each patient had a primary cardiovascular diagnosis with acute renal failure (ARF) and was treated with CVVHDF on the Gambro PRISMA continuous renal replacement therapy (CRRT) machine using the COBE AN69 filter. Independent sample t-test, simple linear regression, ANOVA, and multiple comparisons were used. Simple linear regression revealed that BUN, creatinine, and difference in creatinine (DIFFCRTN) were best predicted by the number of hours of treatment. For every hour of treatment the BUN decreased by .08 mg/dl, the creatinine decreased by .01 mg/dl, and the DIFFCRTN increased by .01 mg/dl. The study concluded that patients on CVVHDF for greater than 72 hours had the greatest changes in BUN and creatinine when a BFR between 135-145 cc/min was used.
Blood urea nitrogen
Cite
Citations (5)
Risk stratification of acute kidney injury (AKI) is important for acute decompensated heart failure (ADHF). The aim of this study was to determine whether clinical markers, such as the blood urea nitrogen/creatinine ratio (BUN/Cr) or BUN or creatinine values alone, stratify the risk of AKI for mortality.In all, 371 consecutive ADHF patients were enrolled in the study. AKI was defined as serum creatinine ≥0.3 mg/dl or a 1.5-fold increase in serum creatinine levels within 48 h. During ADHF therapy, AKI occurred in 99 patients; 55 patients died during the 12-month follow-up period. Grouping patients according to AKI and a median BUN/Cr at admission of 22.1 (non-AKI+low BUN/Cr, non-AKI+high BUN/Cr, AKI+low BUN/Cr, and AKI+high BUN/Cr groups) revealed higher mortality in the AKI+high BUN/Cr group (log-rank test, P<0.001). Cox's proportional hazard analysis revealed an association between AKI+high BUN/Cr and mortality, whereas the association with AKI+low BUN/Cr did not reach statistical significance. When patients were grouped according to AKI and median BUN or creatinine values at admission, AKI was associated with mortality, regardless of BUN or creatinine.The combination of AKI and elevated BUN/Cr, but not BUN or creatinine individually, is linked with an increased risk of mortality in ADHF patients, suggesting that the BUN/Cr is useful for risk stratification of AKI.
Blood urea nitrogen
Cite
Citations (57)
The present studies, the cisplatin treated animals showed a significant increase in blood urea, blood urea nitrogen and serum creatinine. As shown in [Table no:4] serum creatinine, Blood urea nitrogen (BUN), and blood urea levels were significantly higher after 72 h respectively, after administration of single dose of cisplatin when compared to the control group. The pre-treatment with Hydro alcoholic extract of Boerhaavia diffusa (HAEBD) p.o. significantly (P < 0.01) lowered the elevated serum urea creatinine, and Blood urea nitrogen (BUN). When compared to the cisplatin group. The pre-treatment with silymarin showed a marked decrease in concentrations of blood urea, serum creatinine, Blood urea nitrogen and alkaline phosphatise, it was shown that cisplatin treatment induced renal damage and pretreatment with hydro alcoholic extract of Boerhaavia diffusa (HAEBD) provided protective effect against this cisplatin-induced nephrotoxicity. However, before concluding a potential usefulness of hydro alcoholic extract of Boerhaavia diffusa (HAEBD) as adjunct to the cisplatin therapy, further clinical investigation is needed.
Blood urea nitrogen
Nephrotoxicity
Cite
Citations (1)
Blood urea nitrogen
Cite
Citations (24)
Klotho
Homeostasis
Cite
Citations (41)
Increased concentrations of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) often coincide with normal serum phosphorus ([P]s) in chronic kidney disease (CKD). We hypothesized that the phosphate concentration ([P]f) in the cortical distal nephron (CDN) determines [PTH] and [FGF23] in this circumstance.We studied 29 patients with CKD at 4 visits and 28 controls at 1 visit. Assuming GFR = creatinine clearance (Ccr), we examined the following regressions: [P]s on its determinants, EP/Ccr and TRP/Ccr (P excretion and reabsorption per volume of filtrate); [PTH] and [FGF23] on [P]s and EP/Ccr; and TRP/Ccr on [PTH] and [FGF23]. We assumed that EP/Ccr is proportional to [P]f in the CDN.In controls, [P]s correlated with TRP/Ccr but not EP/Ccr. [PTH] and [FGF23] were unrelated to [P]s, EP/Ccr, and TRP/Ccr. In CKD, [P]s correlated with EP/Ccr and TRP/Ccr. [PTH] correlated with [P]s at 2 visits and with EP/Ccr at 4; [FGF23] correlated with [P]s and EP/Ccr at all visits. TRP/Ccr correlated with [FGF23] and [PTH] at one visit each.[P]f in the CDN, not [P]s, determined [PTH] in CKD. Because [FGF23] was consistently associated with only one determinant of [P]s, EP/Ccr, we infer that [P]f also determined [FGF23]. In patients with CKD, we speculate that [P]f in the CDN regulates FGF23 synthesis at that site.
Homeostasis
Cite
Citations (5)
Phosphate homeostasis is maintained by intestine, bone, and kidney, which is regulated by many hormones. In addition to classical hormones such as parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25 (OH) (2)D] , fibroblast growth factor 23 (FGF23) and Klotho have been discovered as novel factors for phosphate metabolism. FGF23 is a circulating hormone that is synthesized by osteocytes and osteoblasts in bone. The physiological actions of FGF23 are to promote phosphaturia and decrease production of 1,25 (OH) (2)D. Klotho was initially identified as an anti-aging protein, but subsequent research revealed multiple functions of Klotho in phosphate metabolism. Klotho directly binds to FGF receptor 1 (FGFR1) and contributes to FGFR1-Klotho complex-mediated signal transduction with higher affinity than FGFR1 or Klotho alone. In addition, the extracellular domain of Klotho is clipped by enzymes and secreted into blood, which exerts phosphaturic effects independently of FGF23. In the regulation of phosphate metabolism, this FGF23-Klotho axis constitutes feedback loops with classical factors such as PTH and 1,25 (OH) (2)D. However, the precise feedback system in the phosphate metabolism remains to be determined and further research is required to provide a greater understanding of the phosphate metabolism system.
Klotho
Bone remodeling
Cite
Citations (1)
Abstract. Tear and blood urea nitrogen, creatinine, and glucose levels were quantitatively analyzed by an enzymatic method in 30 normal patients and in 10 patients with end stage renal disease. The tear and blood samples collected from the end stage renal patients before and after hemodialysis showed that the change in urea nitrogen and creatinine levels in the tears correlated with the change in blood urea nitrogen and creatinine. Tear samples may serve as an alternative, less invasive indicator of serum metabolites in renal patients.
Blood urea nitrogen
Serum urea
Urea nitrogen
Cite
Citations (23)
Acute renal failure (ARF) induced by dextran or mannitol is a lethal adverse effect, and hemodialysis or plasma exchange is recommended to avoid fatal ARF. This report describes 2 cases of ARF; one caused by dextran and the other by mannitol. Both showed decreases in the blood urea nitrogen (BUN)/creatinine ratios after the administration of these reagents. They immediately recovered to the level of creatinine on admission after the administration of these reagents was stopped, without hemodialysis or plasma exchange. Decreases in the BUN/creatinine ratio might be a useful index for the diagnosis of ARF is caused by these reagents.
Blood urea nitrogen
Cite
Citations (10)